Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Bayer A G Ord (OP:BAYZF)

47.45 UNCHANGED

Streaming Delayed Price Updated: 3:58 PM EDT, Apr 8, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	0
Open	47.45
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	47.45
Today's Range	47.45 - 47.45
52wk Range	20.99 - 58.33
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Bayer Announces Leadership Change Within Pharmaceuticals’ Worldwide Markets Organization in the U.S. to Support Company’s Full Growth Potential

March 31, 2026

From Bayer

Via Business Wire

Multiplatinum Rapper, Actor Ludacris Partners with One A Day® to Help People Realize that Health Does Not Need to Be Ludacris

March 26, 2026

From Bayer

Via Business Wire

Performance

YTD	+5.6%	+5.6%
1 Month	+3.1%	+3.1%
3 Month	+3.5%	+3.5%
6 Month	+45.6%	+45.6%
1 Year	+126.1%	+126.1%

More News

KERENDIA® (finerenone) Meets Primary Endpoint in Investigational Phase III FIND-CKD Study in Patients with Non-Diabetic Chronic Kidney Disease

March 16, 2026

From Bayer

Via Business Wire

New FDA 510(k) Clearance Expands Bayer’s MEDRAD® MRXperion MR Injection System Support Across Diverse Range of MR Environments

March 04, 2026

From Bayer

Via Business Wire

Bayer Reports Results for the Investigational Targeted Radionuclide Therapy 225Ac-PSMA-Trillium in Advanced Metastatic Prostate Cancer

February 27, 2026

From Bayer

Via Business Wire

Bayer’s XOFIGO® (radium-223 dichloride) Plus Enzalutamide Demonstrates Significant Overall Survival Benefit in PEACE-3 Trial in Patients With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases

February 26, 2026

From Bayer

Via Business Wire

Bayer Alleges J&J’s Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J’s ERLEADA

February 23, 2026

From Bayer

Via Business Wire

Bayer® Aspirin Partners with Celebrity Chef Jeff Mauro for Immersive Dark Dining Experience This American Heart Month

February 12, 2026

From Bayer

Via Business Wire

Bayer’s Asundexian Demonstrated a Substantial 26% Reduction in Stroke After a Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, With No Increase in ISTH Major Bleeding Versus Placebo

February 05, 2026

From Bayer

Via Business Wire

Bayer Teams Up with Former Professional Quarterback Tony Romo on ‘Highlights REAL’ Campaign

January 29, 2026

From Bayer

Via Business Wire

Bayer to Present Results From Phase III OCEANIC-STROKE Study of Asundexian in Secondary Stroke Prevention

January 27, 2026

From Bayer

Via Business Wire

Bayer and Vanderbilt University Medical Center to Advance Treatments for Cardiovascular and Kidney Diseases

January 20, 2026

From Bayer

Via Business Wire

Bayer Accelerates Pharma Growth on High-Value Portfolio

January 13, 2026

From Bayer

Via Business Wire

Actress and Menopause Advocate Gabrielle Union-Wade Partners with Bayer in the Lynkuet® (elinzanetant) ‘Life Doesn’t Stop for a Hot Flash’ Campaign for Moderate to Severe Hot Flashes Due to Menopause

January 13, 2026

From Bayer

Via Business Wire

Bayer to Expand Into Molecular Imaging With Acquisition of Innovative Pan-Amyloid Radiotracers From Attralus

January 12, 2026

From Bayer

Via Business Wire

Bayer and Soufflé Therapeutics Announce Strategic Collaboration to Advance Cell-Specific Heart-Targeted siRNA Therapy

January 08, 2026

From Bayer

Via Business Wire

Bayer to Present Updates on Pharma Growth Strategy and Pipeline Advancements at J.P. Morgan’s 44th Annual Healthcare Conference

January 05, 2026

From Bayer

Via Business Wire

Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome

December 04, 2025

From Bayer

Via Business Wire

RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints

December 03, 2025

From Bayer

Via Business Wire

Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia

December 02, 2025

From Bayer

Via Business Wire

Bayer’s MEDRAD® Centargo Multi-Patient CT Injection System Now With A Wider Range of Compatible CT Contrast Agents and Presentations

December 01, 2025

From Bayer

Via Business Wire

Bayer’s Asundexian Met Primary Efficacy and Safety Endpoints in Landmark Phase III OCEANIC-STROKE Study in Secondary Stroke Prevention

November 23, 2025

From Bayer

Via Business Wire

U.S. FDA Approves HYRNUO® (sevabertinib) for Previously Treated Patients with HER2-Mutated Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

November 20, 2025

From Bayer

Via Business Wire

Agricultural Conglomerate Bayer Confident In Long-Term Outlook Despite Litigation Risks ↗

November 12, 2025

Via Benzinga

Bayer Launches “Science Delivers” Campaign Celebrating the Transformative Power of Science

November 10, 2025

From Bayer

Via Business Wire

Frequently Asked Questions

Is Bayer A G Ord publicly traded?

Yes, Bayer A G Ord is publicly traded.

What exchange does Bayer A G Ord trade on?

Bayer A G Ord trades on the OTC Traded

What is the ticker symbol for Bayer A G Ord?

The ticker symbol for Bayer A G Ord is BAYZF on the OTC Traded

What is the current price of Bayer A G Ord?

The current price of Bayer A G Ord is 47.45

When was Bayer A G Ord last traded?

The last trade of Bayer A G Ord was at 04/08/26 03:58 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.